Evotec SE Share Price Other OTC
Equities
EVTCY
US30050E1055
Biotechnology & Medical Research
Sales 2024 * | 882M 956M 75.19B | Sales 2025 * | 1.03B 1.12B 88.2B | Capitalization | 1.63B 1.77B 139B |
---|---|---|---|---|---|
Net income 2024 * | -34M -36.87M -2.9B | Net income 2025 * | 31M 33.61M 2.64B | EV / Sales 2024 * | 2.16 x |
Net Debt 2024 * | 278M 301M 23.7B | Net Debt 2025 * | 235M 255M 20.03B | EV / Sales 2025 * | 1.8 x |
P/E ratio 2024 * |
-39.5
x | P/E ratio 2025 * |
35
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.64% |
Latest transcript on Evotec SE
Managers | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 18/06/19 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 06/02/23 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 30/04/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 18/06/19 |
Roland Sackers
BRD | Director/Board Member | 56 | 18/06/19 |
Chairman | 63 | 16/06/14 |
1st Jan change | Capi. | |
---|---|---|
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.32% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |